Cardiologist providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Chiropractor providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Dentist providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Dermatologist providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Family Physician providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
OB-GYN providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Ophthalmologist providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Orthopedic Surgeon providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Pediatrician providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Physical Therapist providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Podiatrist providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Psychiatrist providers include doctors, nurses, nurse practitioners, and physician assistants. They often maintain long-term relationships with you and advise and treat you on a range of health related issues.
Aliu Sanni, MD, FACS, is a Bariatric and General Surgeon at Eastside Bariatric & General Surgery, located in Snellville, Georgia. He commenced his medical training at Newcastle upon Tyne in England before relocating to the United States. He completed his Residency at SUNY Downstate Health Sciences University in New York and his Fellowship at Emory University in Atlanta, Georgia.
Aliu Sanni is the Medical Director at Piedmont Eastside Medical Center for Comprehensive Weight Loss Surgery where he prides himself on providing high-quality care and enhancing the well-being of his patients. Aliu’s vision became a reality with the establishment of Eastside Bariatric & General Surgery. The practice is committed to transforming lives through comprehensive bariatric care in Snellville. Patients are made aware of and empowered towards a lifestyle and prioritizing individual needs through counseling, corrective surgery, and innovative procedures.
Aliu Sanni alongside his committed staff and colleagues, is devoted to guiding each patient towards success on their weight loss journey, fostering a supportive environment where personal health takes center stage. He is also deeply committed to education and serves as a Clinical Professor of Surgery at the Philadelphia College of Osteopathic Medicine Georgia Campus and an Associate Professor of Surgery at the Medical College of Georgia/Augusta University. Responding to the need for hands-on learning, Dr. Sanni has initiated his own internship program.
As a Fellow of the American College of Surgeons and the American Society of Metabolic and Bariatric Surgery, Dr. Sanni remains at the forefront of his field, continuously integrating the latest advancements into his practice.
Outside of medicine, he cherishes his roles as a devoted husband and father, finding joy in playing tennis and soccer in his leisure time. Dr. Sanni's multifaceted involvement in the medical community reflects his unwavering dedication to patient-centered healthcare.
CITI program for the protection of research participants training (Health Information Privacy and Security) (Biomedical Research)
Good Clinical Practices (GCP) trained Work Experience:
Clinical Research Primary and Sub-Investigator at One Health Research Clinic, Inc. Feb, 2017 -Present
Clinical Research Sub-Investigator at Perimeter Institute for Clinical Research, Inc 2014 - 2017
William Bostock & Associates Family Medicine (Pediatrics and Adults) Oct, 2011 - Present
Buford Complete Health and Wellness Center Mar, 2006 - Oct 2011
Clinical Director of Truth's Community Clinic, providing medical, dental and pharmacy needs to the poor 2003 - Present
Southern Surgical Associates 1992 - Mar, 2006
Carraway Methodist Medical Center, Birmingham, Alabama (Internship/Residency - General Surgery) 1987 -1992
Education:
Medical College of Georgia, Augusta, Georgia M.D Academic Achievement: Summa cum Laude 1987
Professional Certification:
American Board of Surgery, Board Certified 1993
Fellow of the American College of Surgeons 1995
Professional Society Memberships:
American Medical Association 1992
Gwinnett/Forsyth County Medical Society 1992
American Board of Surgery, Diplomate 1993
Fellow of the American College of Surgeons 1995
Professional Honors:
Alpha Omega Alpha Honor Medical Society 1986
Clinical Research Trial Expirience:
BAY98-7106/14725: A multicenter, randomized, double-blind, active-controlled study of nifedipine GITS and candesartan in fixed-dose combination in adult subjects with moderate to severe essential hypertension who are naYve to any anti-hypertensive drug treatment (Bayer); 2013.
A Randomized, Double Blind, Placebo-Controlled, Phase m Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea Predominant Irritable Bowel syndrome; Study# 270189661B83002; Furiex Pharmaceuticals; 2013
A Phase ill Clinical Trial to Study the Safety and Efficacy ofMK-1293 Compared to Lantus in Subjects With Type 1 Diabetes Mellitus, Merck Sharp & Dahme Corporation, Principal Investigator, 2013-2016
A Randomized, Placebo-controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus, Duke University/ Amylin Pharmaceuticals, LLC, Principal Investigator, 6/2013- 2016.
A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects with Gout and Cardiovascular Comorbidities. Takeda, 2014.
Effect of Liraglutide on Body Weight in Non-Diabetic Obese Subjects or Overweight Subjects with Co-Morbidities. A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi Centre, Multinational Trial with Stratification of Subject to either 56 or 160 Weeks of Treatment Based on pre-Diabetes Status at Randomization. Novo Nordisk, 7/2014.
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease. Amgen, Inc., 7/2014.
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea Predominant Irritable Bowel Syndrome. Furiex Pharmaceuticals, Sub-Investigator, 11/2012- 8/2014.
A Multicenter Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat versus Placebo on Renal Function in Hyperuricemia and Moderate to Severe Renal Impairment. Takeda, 2014.
AMG 20120138: A Multicenter, Controlled, Open-label Extension (OLE) Study to assess the Long-term Safety and Efficacy of AMO 145 (Amgen); 2013-2016.
AMO 20110116: A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMO 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor (Amgen); 2013- 2016.
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMO 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease. Amgen, Inc, 2014- 2016.
Phase III Trial to Confirm the Anti-angina! Effect of T89 in Patients with Stable Angina (CAESA Study), Tasly Pharmaceuticals, Inc, Principal Investigator, 7/2014-2016.
A Phase 2, Randomized , Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects with Gout and Moderate Renal Impairment, Takeda Development Center Americas, Inc, Principal Investigator, 8/2014-2016.
A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) with Sitagliptin Compared with Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects with T2DM With Inadequate Glycemic Control on Metformin Monotherapy, Merck Sharp & Dohme Corporation, Principal Investigator, 12/2014- 2016.
A Randomized, double-blind, double-dummy, parallel-group, multi-center Phase IIb study to assess the efficacy and safety of different dose combinations of an aromatase inhibitor and a progestin in an intravaginal ring versus placebo and leuprorelin/ leuprolide acetate in women with symptomatic endometriosis over a 12 week treatment period; Bayer HealthCare AG; Study Number: Bay 98-7196 I 15832; 2015
"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Parallel Group Multi-Center Study To Evaluate The Efficacy and Safety ofTTP273 Following of 12 Weeks Administration In Subject With Type 2 Diabetes Mellitus On a Stable Dose of Metformin"; Sponsor: vTv Therapeutics; Protocol#; TTP273-201; 5/ 2016-2017
A Phase III Study to Evaluate the Efficacy and Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women; Protocol#: M12-815; Sponsor: AbbVie; 4/2016-2017
A Phase III Study to Evaluate the Efficacy and Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis Associated Pain; Protocol#: M12-702; Sponsor: AbbVie; 4/2016- 2017
A Phase 3 Double-Blind, Placebo-Controlled study to assess the efficacy, safety, and tolerability ofNKTR-181 in Opioid Naive Subjects with Moderate to Severe Chronic Low Back Pain; Nektar Therapeutics; Protocol Number: 14-181-07; 3/2016
A Phase 3 Double-Blind, Placebo-Controlled study to assess the efficacy, safety, and tolerability ofNKTR-181 in Opioid Naive Subjects with Moderate to Severe Chronic Noncancer Pain; Nektar Therapeutics; Protocol Number: 14-181-08; 3/ 2016
A Phase 3 Randomized, Double-Blind, Active-Controlled, Multicenter Study of The Long-Term Safety and Efficacy Of Subcutaneous administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee; Sponsor: Pfizer; Protocol#: A4091058; 3/2016
A Phase 3, Multicenter, Long-Term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement; Sponsor: Pfizer; Protocol #: A4091064; 3/ 2016.
A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVNIOOO in Subjects with External Genital Warts and Perianal Warts; Sponsor: Novan, Inc.; Protocol#: NI-WA201; 5/2016.
A Phase 3 Double-Blind, Placebo-Controlled study to assess the efficacy, safety, and tolerability ofNKTR-181 in Opioid Naive Subjects with Moderate to Severe Chronic Low Back Pain; Nektar Therapeutics; Protocol Number: 14-181-07; 2016.
A randomized, double blind, placebo-controlled, phase 2b dose ranging study to assess the efficacy and safety of OBE2l 09 in subject with endometriosis associated pain.
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add back therapy for management of heavy menstrual bleeding associated with uterine fibroids in premenopausal woman.
Liberty 2: An International Phase 3 Randomized, Double-blind, Placebo-Controlled Efficiancy and Safety study to Evaluate Relugolix Co-Administered with and ,without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids.
Spitit l: An International Phase 3 Randomized, Double -blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolis Administered with and sithout Low-Dose Estrodiol and Norc1hindrone Acetate in Women with Endometriosis-Associated Pain.
A 26 week, Multicenter, Randomized, Placebo-Controlled, Double Blind, Parallel Group, Phase 3 Trial with a 26 week Safety Extention Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age
A Phase 3, Open-lable, Multicenter, 12 month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactiveity Disorder.
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Sfery Study ofSHP465 in Children Aged 6-12 years with Attention-Deficit/Hyperactive Disorder(ADHD)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular
Safety of Filgotinib in Adult Males with Moderately to Severely Active Ulcerative Colitis
A Randomized, Double blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely to Severely Active Inflamatory Bowl Disease.
Dr. Ray Kotwicki, MD, MPH, DFAPA is the President and Chief Medical Officer of Intensive Outpatient Services at Hightop Health. Until June, 2023 he served as Chief Strategy Officer and before that, the Charles B. West Chief Medical Officer at Skyland Trail, an Atlanta, Georgia-based nationally acclaimed private, nonprofit residential and day treatment organization for adults and adolescents with mental illnesses. Kotwicki also held leadership positions as the Medical Director of Community Outreach Services at Grady Health System as well as Director of Medical Student Education for the Department of Psychiatry and Behavioral Sciences at the Emory University School of Medicine
Kotwicki trained as a Department of Energy Fellow and was a Medical Scholar at the University of Wisconsin Medical School. He completed post-graduate training at Harvard Medical School, the Boston University School of Medicine, and Emory University, where he earned a Master in Public Health degree in Health Policy and Management. He remains a full professor on the adjunctive faculty at both the Emory University School of Medicine as well as the Rollins School of Public Health. Kotwicki has presented more than 425 invited lectures, symposia, and seminars to thousands of attendees. He is recognized as a trusted national expert and renowned speaker on current issues in psychiatry, mental health, professionalism, and wellness.
Kotwicki is a Diplomate of the American Board of Psychiatry and Neurology and is a Past President of the Georgia Psychiatric Physicians’ Association. He currently serves as Vice President of the Executive Council of the Southern Psychiatric Association. Kotwicki was a member of the Leadership Atlanta Class of 2011 and served as President of the Board of Directors of Positive Impact, the Southeast’s premiere HIV mental health program for three years. He also served as a member of the Board of Trustees of The Lovett School until 2022 and was elected to the American College of Psychiatrists in 2019. Throughout his career, Dr. Kotwicki has received numerous distinctions, including Georgia Psychiatric Physicians Association’s 2019-2020 Psychiatrist of the Year award, Emory University’s most prestigious Dean’s “Golden Apple” Teaching Award, Alpha Omega Alpha Medical Honor Society, Mental Health America and Eli Lilly’s “Heroes in Fight” Clinical Team Award, and the National Alliance on Mental Illness’ Exemplary Psychiatrist Award. Kotwicki received the Rollins School of Public Health at Emory University’s “Distinguished Achievement Alumnus Award” in 2017.
Dr. Elaine Carelus is a native New Yorker born and raised in Freeport, NY. She earned her combined BS/MS degree in Biological Sciences from St. John's University, Queens NY. She earned an additional master's degree in Biomedical Sciences from Stony Brook University in Stony Brook, NY. She then completed medical school earning an MD at the Renaissance School of Medicine at Stony Brook University. There she developed a love and passion for surgery. She completed her general surgery residency training at Montefiore Medical Center in The Bronx, NY. She is now excited to further her surgical career as a Bariatric Surgery Fellow here at Peachtree Surgical and Bariatrics.
Titus Duncan, MD, is a general and bariatric surgeon and the president and CEO of Peachtree Surgical & Bariatrics, located in the Buckhead area of Atlanta, Georgia. He is also a GERD/reflux specialist who is board certified in general surgery and has extensive training in weight loss surgery, minimally invasive surgery, and revision bariatric surgery. He is a fellow of the American College of Surgeons.
Dr. Duncan holds clinical status at Morehouse School of Medicine as an Associate Professor of Surgery and is Director of Minimally Invasive and Bariatric Surgery at Morehouse and Atlanta Medical Center. He currently serves on the Executive Council of the ASMBS (American Society of Metabolic and Bariatric Surgery).
Dr. Duncan has published extensively in the field of minimally invasive weight loss and general surgery. He is regarded as a pioneer in the field and has taught and lectured extensively around the world about minimally invasive and bariatric surgical techniques. He is Director of a Minimally Invasive and Bariatric Fellowship specializing in training other surgeons to perform these delicate procedures.
“I was taken care of from beginning to the end very professional and kind staff Dr Duncan was amazing I felt very comfortable and she called me back on how the procedure went Amazing Dr”
2939 Titus Duncan, MD
Specialist
4200 Northside Parkway N.W.
Building 8, Ste. 200
Atlanta, GA 30327
4.67(64)
Dr. Raymond Kotwicki, MD, MPH
Psychiatrist 14.6 mi
Dr. Ray Kotwicki, MD, MPH, DFAPA is the President and Chief Medical Officer of Intensive Outpatient Services at Hightop Health. Until June, 2023 he served as Chief Strategy Officer and before that, the Charles B. West Chief Medical Officer at Skyland Trail, an Atlanta, Georgia-based nationally acclaimed private, nonprofit residential and day treatment organization for adults and adolescents with mental illnesses. Kotwicki also held leadership positions as the Medical Director of Community Outreach Services at Grady Health System as well as Director of Medical Student Education for the Department of Psychiatry and Behavioral Sciences at the Emory University School of Medicine
Kotwicki trained as a Department of Energy Fellow and was a Medical Scholar at the University of Wisconsin Medical School. He completed post-graduate training at Harvard Medical School, the Boston University School of Medicine, and Emory University, where he earned a Master in Public Health degree in Health Policy and Management. He remains a full professor on the adjunctive faculty at both the Emory University School of Medicine as well as the Rollins School of Public Health. Kotwicki has presented more than 425 invited lectures, symposia, and seminars to thousands of attendees. He is recognized as a trusted national expert and renowned speaker on current issues in psychiatry, mental health, professionalism, and wellness.
Kotwicki is a Diplomate of the American Board of Psychiatry and Neurology and is a Past President of the Georgia Psychiatric Physicians’ Association. He currently serves as Vice President of the Executive Council of the Southern Psychiatric Association. Kotwicki was a member of the Leadership Atlanta Class of 2011 and served as President of the Board of Directors of Positive Impact, the Southeast’s premiere HIV mental health program for three years. He also served as a member of the Board of Trustees of The Lovett School until 2022 and was elected to the American College of Psychiatrists in 2019. Throughout his career, Dr. Kotwicki has received numerous distinctions, including Georgia Psychiatric Physicians Association’s 2019-2020 Psychiatrist of the Year award, Emory University’s most prestigious Dean’s “Golden Apple” Teaching Award, Alpha Omega Alpha Medical Honor Society, Mental Health America and Eli Lilly’s “Heroes in Fight” Clinical Team Award, and the National Alliance on Mental Illness’ Exemplary Psychiatrist Award. Kotwicki received the Rollins School of Public Health at Emory University’s “Distinguished Achievement Alumnus Award” in 2017.
Dr. Ray Kotwicki, MD, MPH, DFAPA is the President and Chief Medical Officer of Intensive Outpatient Services at Hightop Health. Until June, 2023 he served as Chief Strategy Officer and before that, the Charles B. West Chief Medical Officer at Skyland Trail, an Atlanta, Georgia-based nationally acclaimed private, nonprofit residential and day treatment organization for adults and adolescents with mental illnesses. Kotwicki also held leadership positions as the Medical Director of Community Outreach Services at Grady Health System as well as Director of Medical Student Education for the Department of Psychiatry and Behavioral Sciences at the Emory University School of Medicine
Kotwicki trained as a Department of Energy Fellow and was a Medical Scholar at the University of Wisconsin Medical School. He completed post-graduate training at Harvard Medical School, the Boston University School of Medicine, and Emory University, where he earned a Master in Public Health degree in Health Policy and Management. He remains a full professor on the adjunctive faculty at both the Emory University School of Medicine as well as the Rollins School of Public Health. Kotwicki has presented more than 425 invited lectures, symposia, and seminars to thousands of attendees. He is recognized as a trusted national expert and renowned speaker on current issues in psychiatry, mental health, professionalism, and wellness.
Kotwicki is a Diplomate of the American Board of Psychiatry and Neurology and is a Past President of the Georgia Psychiatric Physicians’ Association. He currently serves as Vice President of the Executive Council of the Southern Psychiatric Association. Kotwicki was a member of the Leadership Atlanta Class of 2011 and served as President of the Board of Directors of Positive Impact, the Southeast’s premiere HIV mental health program for three years. He also served as a member of the Board of Trustees of The Lovett School until 2022 and was elected to the American College of Psychiatrists in 2019. Throughout his career, Dr. Kotwicki has received numerous distinctions, including Georgia Psychiatric Physicians Association’s 2019-2020 Psychiatrist of the Year award, Emory University’s most prestigious Dean’s “Golden Apple” Teaching Award, Alpha Omega Alpha Medical Honor Society, Mental Health America and Eli Lilly’s “Heroes in Fight” Clinical Team Award, and the National Alliance on Mental Illness’ Exemplary Psychiatrist Award. Kotwicki received the Rollins School of Public Health at Emory University’s “Distinguished Achievement Alumnus Award” in 2017.
Nathan Kalil, DPM, AACFAS is a Fellowship-Trained Foot and Ankle Surgeon and Podiatrist. Dr. Kalil received his Bachelors of Science in Biochemistry from Baylor University in Waco, TX in 2014, and received his Doctorate of Podiatric Medicine Degree from Kent State University College of Podiatric Medicine in Independence, OH in 2020. He completed his residency training at St. Vincent Charity Medical Center and University Hospitals in Cleveland, OH. Dr. Kalil then completed an Advanced Reconstructive Foot & Ankle Surgery Fellowship at The Reconstruction Institute in Bellevue, OH where he had the opportunity to further his training in the surgical and non-surgical management of severe foot and ankle conditions, such as end stage arthritis, trauma and post-traumatic arthritis, deformity correction, and revision surgeries using the latest cutting edge technology, such as the design and use of custom 3D-printed implants, while being actively involved in research, authoring several scientific posters and peer-reviewed articles, and has presented at both local and national podiatric meetings. Dr. Kalil is dedicated to providing compassionate patient-centered care to all of our patients. Dr Kalil says, “I am excited and blessed to have the opportunity to join the Modern Podiatry team and serve the community. I am passionate about providing individualized treatment plans to help keep patients active and improve their quality of life in an effort to eliminate their foot and ankle pain.” Dr. Kalil is currently accepting patients at Modern Podiatry's Griffin location.
Nathan Kalil, DPM, AACFAS is a Fellowship-Trained Foot and Ankle Surgeon and Podiatrist. Dr. Kalil received his Bachelors of Science in Biochemistry from Baylor University in Waco, TX in 2014, and received his Doctorate of Podiatric Medicine Degree from Kent State University College of Podiatric Medicine in Independence, OH in 2020. He completed his residency training at St. Vincent Charity Medical Center and University Hospitals in Cleveland, OH. Dr. Kalil then completed an Advanced Reconstructive Foot & Ankle Surgery Fellowship at The Reconstruction Institute in Bellevue, OH where he had the opportunity to further his training in the surgical and non-surgical management of severe foot and ankle conditions, such as end stage arthritis, trauma and post-traumatic arthritis, deformity correction, and revision surgeries using the latest cutting edge technology, such as the design and use of custom 3D-printed implants, while being actively involved in research, authoring several scientific posters and peer-reviewed articles, and has presented at both local and national podiatric meetings. Dr. Kalil is dedicated to providing compassionate patient-centered care to all of our patients. Dr Kalil says, “I am excited and blessed to have the opportunity to join the Modern Podiatry team and serve the community. I am passionate about providing individualized treatment plans to help keep patients active and improve their quality of life in an effort to eliminate their foot and ankle pain.” Dr. Kalil is currently accepting patients at Modern Podiatry's Griffin location.
Nathan Kalil, DPM, AACFAS is a Fellowship-Trained Foot and Ankle Surgeon and Podiatrist. Dr. Kalil received his Bachelors of Science in Biochemistry from Baylor University in Waco, TX in 2014, and received his Doctorate of Podiatric Medicine Degree from Kent State University College of Podiatric Medicine in Independence, OH in 2020. He completed his residency training at St. Vincent Charity Medical Center and University Hospitals in Cleveland, OH. Dr. Kalil then completed an Advanced Reconstructive Foot & Ankle Surgery Fellowship at The Reconstruction Institute in Bellevue, OH where he had the opportunity to further his training in the surgical and non-surgical management of severe foot and ankle conditions, such as end stage arthritis, trauma and post-traumatic arthritis, deformity correction, and revision surgeries using the latest cutting edge technology, such as the design and use of custom 3D-printed implants, while being actively involved in research, authoring several scientific posters and peer-reviewed articles, and has presented at both local and national podiatric meetings. Dr. Kalil is dedicated to providing compassionate patient-centered care to all of our patients. Dr Kalil says, “I am excited and blessed to have the opportunity to join the Modern Podiatry team and serve the community. I am passionate about providing individualized treatment plans to help keep patients active and improve their quality of life in an effort to eliminate their foot and ankle pain.” Dr. Kalil is currently accepting patients at Modern Podiatry's Griffin location.
/assets/images/provider/photos/2545243.png)
/assets/images/provider/photos/2545243.png)
